Eagle Pharmaceuticals
50 Tice Blvd, Suite 315
Woodcliffe Lake
New Jersey
07677
United States
Tel: (201) 326-5300
Website: https://www.eagleus.com/
195 articles with Eagle Pharmaceuticals
-
Eagle Pharmaceuticals’ Presentation at Piper Sandler 32nd Annual Virtual Healthcare Conference Available for Viewing
11/23/2020
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Company’s pre-recorded presentation at the Piper Sandler 32nd Annual Virtual Healthcare Conference
-
Eagle Pharmaceuticals Reports Third Quarter 2020 Results
11/2/2020
Q3 2020 net income was $0.52 per basic and $0.51 per diluted share and adjusted non-GAAP net income was $1.19 per basic and $1.17 per diluted share
-
Eagle Pharmaceuticals Strengthens Management Team to Prepare for Future Growth
11/2/2020
Key additions deepen scientific, analytics and commercial expertise; positions Eagle to advance product pipeline and prepare for future commercial launches in oncology and critical care businesses
-
Eagle Pharmaceuticals to Discuss Third Quarter 2020 Financial Results on November 2, 2020
10/26/2020
Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2020 third quarter financial results on Monday, November 2, 2020, before the market opens. Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will host a conference call to discuss the results as follows: Date Monday, November 2, 2020
-
Eagle Pharmaceuticals Commences $25 Million Accelerated Share Repurchase as Part of Existing $160 Million Share Repurchase Program
9/24/2020
Eagle Pharmaceuticals, Inc. announced that its Board of Directors has approved a $25 million accelerated share repurchase transaction with JPMorgan Chase Bank, National Association as part of the Company’s existing $160 million share repurchase program.
-
Eagle Pharmaceuticals’ Japanese Licensing Partner, SymBio, Receives Approval of TREAKISYM Ready-To-Dilute (“RTD”) Formulation, with Launch Expected in January 2021
9/23/2020
Eagle Pharmaceuticals, Inc. announced that its marketing partner, SymBio Pharmaceuticals Limited, has received regulatory approval for TREAKISYM ready-to-dilute liquid formulation from the Pharmaceuticals and Medical Devices Agency in Japan.
-
Eagle Pharmaceuticals to Present at Upcoming September 2020 Healthcare Conferences
9/8/2020
Eagle Pharmaceuticals, Inc. announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at two upcoming conferences in September.
-
Eagle Pharmaceuticals Announces Publication of Preclinical Study of Intranasal Dantrolene in Journal of Alzheimer’s Disease
8/19/2020
Eagle Pharmaceuticals, Inc. announced that preclinical research on dantrolene sodium was published today in the peer-reviewed Journal of Alzheimer’s Disease.1 The article reported results from an academic-based study that demonstrated dantrolene sodium administered intranasally improved both memory and cognition in a mouse model of Alzheimer’s disease.
-
Eagle Pharmaceuticals Reports Second Quarter 2020 Results
8/10/2020
-- Q2 2020 net loss was ($0.02) per basic and diluted share and adjusted non-GAAP net income was $0.59 per basic and $0.57 per diluted share -- -- Anticipate launch of vasopressin, maintaining our 180-day market exclusivity -- -- CMS establishes unique J-code for PEMFEXY™ (pemetrexed for injection); FDA granted supplement approval for 500mg multiple-dose vial -- -- Received positive additional data for the Company’s fulvestrant product candida
-
Eagle Pharmaceuticals to Discuss Second Quarter 2020 Financial Results on August 10, 2020
8/3/2020
Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2020 second quarter financial results on Monday, August 10, 2020, before the market opens.
-
CMS Establishes Unique J-Code for Eagle Pharmaceuticals’ PEMFEXY™ (Pemetrexed for Injection)
7/9/2020
Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) today announced that the Centers for Medicare & Medicaid Services (CMS) has established a unique, product-specific billing code for PEMFEXY™ (pemetrexed for injection)
-
It’s a relatively slow month ahead for July in terms of PDUFA dates for the U.S. FDA. However, there are several dates pending throughout the month. Here’s a look at three for the next two weeks.
-
Eagle Pharmaceuticals to Present at June Investor Conferences
5/26/2020
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at two upcoming investor conferences as follows:
-
Eagle Pharmaceuticals Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders
5/22/2020
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle”) announced today that, due to public health and safety concerns related to the ongoing COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees and others, Eagle is changing its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) to a virtual-only fo
-
Eagle Pharmaceuticals to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference
5/12/2020
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will host a fireside chat at the 2020 RBC Capital Markets Global Healthcare Virtual Conference
-
Eagle Pharmaceuticals Reports First Quarter 2020 Results
5/11/2020
Eagle Pharmaceuticals, Inc. announced financial results for the three months ended March 31, 2020.
-
Eagle Pharmaceuticals Advances Novel and Proprietary Formulation of Fulvestrant Product Candidate EA-114; Company to Request Additional Meeting with U.S. Food and Drug Administration (“FDA”)
5/4/2020
Eagle Pharmaceuticals, Inc. provided an update on its pilot clinical study to assess the unique characteristics of its fulvestrant product candidate, EA-114, which has the potential to enhance estrogen receptor inhibition and improve patient outcomes.
-
Eagle Pharmaceuticals to Discuss First Quarter 2020 Financial Results on May 11, 2020
4/29/2020
Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2020 first quarter financial results on Monday, May 11, 2020, before the market opens.
-
Shares of Eagle Pharmaceuticals and Teva Pharmaceuticals are climbing following a favorable ruling in U.S. District Court that protects the patent for cancer drug Bendeka from generic competition through 2031.
-
Court Issues Favorable Patent Litigation Decision for Eagle Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Ltd. for BENDEKA (bendamustine hydrochloride injection)
4/28/2020
Eagle Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Ltd. announced that on April 27, 2020, the U.S. District Court for the District of Delaware has issued a patent decision in favor of Eagle and Teva for BENDEKA®, a liquid, low-volume and short-time 10-minute infusion formulation of bendamustine hydrochloride..